1 |
MITELMAN F, JOHANSSON B, MERTENS F. The impact of translocations and gene fusions on cancer causation[J]. Nat Rev Cancer, 2007, 7(4):233-245.
|
2 |
MORIN S J, ECCLES J, ITURRIAGA A, et al. Translocations, inversions and other chromosome rearrangements[J]. Fertil Steril, 2017, 107(1):19-26.
|
3 |
张得芳. 染色体重排与物种分化[J]. 分子植物育种, 2017, 15(1):279-289.
|
4 |
RAY-COQUARD I, SERRE D, REICHARDT P,et al. Options for treating different soft tissue sarcoma subtypes[J]. Future Oncol, 2018, 14(10s):25-49.
|
5 |
BILL M, MRÓZEK K, KOHLSCHMIDT J, et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A[J].Proc Natl Acad Sci U S A,2020, 117(42):26340-26346.
|
6 |
KHAN M, SIDDIQI R, TRAN TH. Philadelphia chromosome-like acute lymphoblastic leukemia:A review of the genetic basis, clinical features,and therapeutic options[J]. Semin Hematol, 2018, 55(4):235-241.
|
7 |
OSMAN A E G, DEININGER M W. Chronic myeloid leukemia: modern therapies, current challenges and future directions[J]. Blood Rev, 2021:100825.
|
8 |
SCHRÖDER J, KUMAR A, WONG S Q. Overview of fusion detection strategies using next-generation sequencing[J]. Methods Mol Biol, 2019, 1908:125-138.
|
9 |
STANGL C, DE BLANK S, RENKENS I, et al. Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing[J]. Nat Commun, 2020, 11(1):2861.
|
10 |
WANG Y, WU N, LIU D, et al. Recurrent fusion genes in leukemia: an attractive target for diagnosis and treatment[J]. Curr Genomics, 2017, 18(5):378-384.
|
11 |
Mertens F, Johansson B, Fioretos T, et al. The emerging complexity of gene fusions in cancer[J]. Nat Rev Cancer, 2015, 15(6):371-381.
|
12 |
KIM P, ZHOU X. Fusion GDB: fusion gene annotation DataBase[J].Nucl Acids Res,2019,47(D1):D994-d1004.
|
13 |
NARDI V, KU N, FRIGAULT M J, et al. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement[J]. Blood Adv, 2020, 4(1):106-111.
|
14 |
BIELACK S S, COX M C, NATHRATH M, et al. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion[J]. Ann Oncol, 2019, 30():viii31-viii35.
|
15 |
DRILON A, LI G, DOGAN S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)[J]. Ann Oncol, 2016, 27(5):920-926.
|
16 |
FRENCH C A. NUT carcinoma: Clinicopathologic features, pathogenesis, and treatment[J]. Pathol Int, 2018, 68(11):583-595.
|
17 |
DE BRAEKELEER E, DOUET-GUILBERT N, DE BRAEKELEER M. RARA fusion genes in acute promyelocytic leukemia: a review[J]. Expert Rev Hematol, 2014, 7(3):347-357.
|
18 |
NI X, HU G, CAI X. The success and the challenge of all-trans retinoic acid in the treatment of cancer[J]. Crit Rev Food Sci Nutr, 2019, 59(sup1):S71-S80.
|
19 |
CLAUDIANI S, APPERLEY J F. The argument for using imatinib in CML[J]. Hematology Am Soc Hematol Educ Program, 2018, 2018(1):161-167.
|
20 |
FRENCH C A. Pathogenesis of NUT midline carcinoma[J]. Annu Rev Pathol, 2012, 7:247-265.
|
21 |
PAPAEMMANUIL E, GERSTUNG M, BULLINGER L,et al.Genomic classification and prognosis in acute myeloid leukemia[J]. N Engl J Med, 2016, 374(23):2209-2221.
|
22 |
WAGENER R, LÓPEZ C, KLEINHEINZ K, et al. IG-MYC (+) neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas[J]. Blood, 2018, 132(21):2280-2285.
|
23 |
JANZ S. Myc translocations in B cell and plasma cell neoplasms[J]. DNA Repair (Amst), 2006, 5(9/10):1213-1224.
|
24 |
DANG C V. MYC on the path to cancer[J]. Cell, 2012, 149(1):22-35.
|
25 |
LARMONIE N S, DIK W A, MEIJERINK J P, et al. Breakpoint sites disclose the role of the V(D)J recombination machinery in the formation of T-cell receptor (TCR) and non-TCR associated aberrations in T-cell acute lymphoblastic leukemia[J]. Haematologica, 2013, 98(8):1173-1184.
|
26 |
HAO X, BILLINGS S D, WU F, et al. Dermatofibrosarcoma protuberans: update on the diagnosis and treatment[J]. J Clin Med, 2020,9(6):1752.
|
27 |
OTSUKA-MAEDA S, KAJIHARA I, KANEMARU H,et al. Retrospective study of COL1A1-PDGFB fusion gene-positive dermatofibrosarcoma protuberans in Kumamoto University[J]. Clin Exp Dermatol,2020, 45(8):1067-1068.
|
28 |
KÖSTER J, ARBAJIAN E, VIKLUND B, et al. Genomic and transcriptomic features of dermatofibrosarcoma protuberans: Unusual chromosomal origin of the COL1A1-PDGFB fusion gene and synergistic effects of amplified regions in tumor development[J]. Cancer Genet, 2020, 241:34-41.
|
29 |
LI N, ZHOU T, CHEN S, et al. COL1A1-PDGFB gene fusion in dermatofibrosarcoma protuberans: a useful diagnostic tool and clinicopathological analysis[J]. Int J Clin Exp Pathol, 2018, 11(8):4052-4059.
|
30 |
MIETTINEN M, FELISIAK-GOLABEK A, LUIÑA CONTRERAS A, et al. New fusion sarcomas: histopathology and clinical significance of selected entities[J]. Hum Pathol, 2019, 86:57-65.
|
31 |
WANG Z, WANG Y, ZHANG J, et al. Significance of the TMPRSS2:ERG gene fusion in prostate cancer[J]. Mol Med Rep, 2017, 16(4):5450-5458.
|
32 |
LIMSUWANACHOT N, KONGRUANG A, RERKAMNUAYCHOKE B, et al. Practical laboratory tools for monitoring of BCR-ABL1 transcripts and tyrosine kinase (TK) domain mutations in chronic myeloid leukemia patients undergoing TK inhibitor therapy: a single-center experience in thailand[J]. Asian Pac J Cancer Prev, 2020, 21(7):2003-2012.
|
33 |
赵 亮, 张 丽, 曾 强,等. ABL1相关融合基因与急性淋巴细胞性白血病关系的研究进展[J]. 中国慢性病预防与控制, 2016, 24(5):383-386.
|
34 |
郑 岚, 郑 浩, 姚晓玲. 白血病相关融合基因的研究进展 [J]. 淮海医药, 2018, 36(5):624-628.
|
35 |
LAXMI A, GUPTA P, GUPTA J. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target[J]. Cancer Biomark, 2019, 24(4):383-393.
|
36 |
DE BRAEKELEER E, DOUET-GUILBERT N, ROWE D, et al. ABL1 fusion genes in hematological malignancies:a review[J].Eur J Haematol,2011,86(5):361-371.
|
37 |
SUNDARESH A.WILLIAMS O. Mechanism of ETV6-RUNX1 Leukemia[J]. Adv Exp Med Biol, 2017, 962:201-216.
|
38 |
冯业成, 黄慧敏, 符垂师. 小儿急性髓性白血病的CDKN2A和CDKN2B的拷贝数变异情况分析 [J]. 临床肿瘤学杂志, 2020, 25(9):830-835.
|
39 |
SILVEIRA ZAVALHIA L, WEBER MEDEIROS A, OLIVEIRA SILVA A, et al. Do FHIT gene alterations play a role in human solid tumors?[J]. Asia Pac J Clin Oncol, 2018, 14(5):e214-e223.
|
40 |
COLLIN A. NUT (nuclear protein in testis) [J]. Atlas Genet Cytogenet Oncol Haematol, 2007,11(3):207-208.
|
41 |
FRENCH C A. NUT midline carcinoma[J]. Cancer Genet Cytogenet, 2010, 203(1):16-20.
|
42 |
CHIANG C M. Phospho-BRD4: transcription plasticity and drug targeting[J]. Drug Discov Today Technol, 2016, 19:17-22.
|
43 |
SAKAMAKI J I, WILKINSON S, HAHN M, et al. Bromodomain protein BRD4 is a transcriptional repressor of autophagy and lysosomal function[J]. Mol Cell, 2017, 66(4):517-532.e519.
|
44 |
ALEKSEYENKO A A, WALSH E M, ZEE B M,et al.Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma[J]. Proc Natl Acad Sci U S A, 2017, 114(21):E4184-E4192.
|
45 |
GRÜNEWALD T G, BERNARD V, GILARDI-HEBENSTREIT P,et al.Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite[J]. Nat Genet,2015, 47(9):1073-1078.
|
46 |
SLANY R K. MLL fusion proteins and transcriptional control[J]. Biochim Biophys Acta Gene Regul Mech, 2020, 1863(3):194503.
|
47 |
SWART L E, HEIDENREICH O. The RUNX1/RUNX1T1 network: translating insights into therapeutic options[J]. Exp Hematol, 2021,94:1-10.
|
48 |
FU L, SHI J, LIU A, et al. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia[J]. Int J Cancer, 2017, 140(3):653-661.
|
49 |
AL-HARBI S, ALJURF M, MOHTY M, et al. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1[J].Blood Adv,2020,4(1):229-238.
|
50 |
NAPOLITANO M, VENTURELLI M, MOLINARO E,et al. NUT midline carcinoma of the head and neck: current perspectives[J]. Onco Targets Ther, 2019, 12:3235-3244.
|
51 |
ZHANG X, ZEGAR T, LUCAS A, et al. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma[J]. Oncogene, 2020, 39(24):4770-4779.
|
52 |
OTSUBO R, MUSSAZHANOVA Z, AKAZAWA Y, et al. Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature[J]. J Pediatr Endocrinol Metab, 2018, 31(4):461-467.
|
53 |
WU B, LOH T K S, VANECEK T, et al. (Mammary Analogue) Secretory carcinoma of the nasal cavity: report of a rare case with p63 and DOG1 expression and uncommon exon 4-exon 14 ETV6-NTRK3 fusion diagnosed with next generation sequencing[J]. Head Neck Pathol, 2020, 14(2):542-549.
|